There are still uncertainties about the existence of protective immunity and the duration of protective antibodies in patients infected with SARS-CoV-2. Serological testing is an appropriate tool for epidemiological investigations to assess the persistence of antibodies over time. The nature of the immune response induced by this virus is also poorly understood. This ancillary study aims at assessing the immunological characteristics of patients that participated in the NOSO-COR study at Hospices Civils de Lyon six and twelve months after the initial infectious episode. Two visits will be scheduled at 6 and 12 months (± 1 month) after the initial SARS-CoV-2 infectious episode, Blood, saliva and nasopharyngeal samples will be collected for seroprevalence and immunological investigation.
Other: Collection of blood, salivary and nasopharyngeal samples.
Each visit M6 and M12
Blood: 1 PAXgene tube (2.5mL) 1 EDTA tube (4mL), 1 dry tube with gel (5mL), 3 EDTA tubes (10mL each)
Salivary sample
Nasopharyngeal sample
Inclusion Criteria:
SARS-CoV-2 confirmed by RT-PCR
- Adults > 18 years
- Signed consent form
- Affiliated to the French health system
Exclusion Criteria:
- Pregnant women
- Hospitalized patients
- Individuals subject to legal protection
- Imprisoned individuals
- Individuals who have expressed an opposition to participate, or who do not wish to
donate blood samples
Service épidémiologie, Hopital édouard Herriot
Lyon, Rhone, France
hopital Edouard Herriot
Lyon, France
Philippe VANHEMS, MD, Principal Investigator
Lyon, France, 69003